![]() The participants were asked to declare themselves a morning or evening person clearly or to some extent. Jaakko Kaprio, from the Finnish Twin Cohort study at the University of Helsinki, followed nearly 23,000 men and women, all twins and aged 24. To understand what was happening, Hublin and Dr. Researchers were inspired to do this study by past studies that had linked night owls to a higher risk of disease, including heart problems.Īmong those were data from the UK Biobank published as part of a 2018 study that found a small increased risk of death from any cause including disease, and from heart conditions, in evening types. "This is compared to those who are clearly 'morning' persons." "In addition, the increased risk of mortality associated with being a clearly 'evening' person appears to be mainly accounted for by a larger consumption of tobacco and alcohol," Hublin said in a journal news release. Christer Hublin, from the Finnish Institute of Occupational Health in Helsinki. "Our findings suggest that there is little or no independent contribution of chronotype to mortality," said study author Dr. The findings were published June 15 in the journal Chronobiology International. Researchers studied twins in Finland for 37 years, looking at different chronotypes, the body's natural inclination to sleep at a certain time.Īlthough they saw that the evening types had a slightly increased risk of dying than the morning types, it was those other habits that were at the root of that greater likelihood of premature death, the study found. The transaction is not material to ResMed’s consolidated financial results its financial terms were not disclosed.It's not the late nights, but the smoking and drinking that happen during those late nights, that are killing people who are "night owls" earlier in life, a new study claims. It will take the combined efforts of sleep labs and connected home solutions like NightOwl to identify a significant portion of the hundreds of millions of people suffering from this disease that don’t even know it.”Įctosense will operate within ResMed’s Sleep and Respiratory Care business. We’re excited to welcome Ectosense’s life-changing team to the ResMed family.”įrederik Massie, chief technology officer and cofounder of Ectosense, says in a release, “ResMed has the global reach and passionate ambition to help increase patient access to Ectosense’s proven diagnostic solution and a path to better sleep and overall health. Ectosense’s clinically validated, consumer-friendly devices will enable us to help millions of people in many markets improve their sleep and overall health. Justin Leong, ResMed president of Asia and Latin America, says in a release, “In developing markets, we need to make sleep tests affordable, accessible and easy to use. ResMed plans to focus on scaling up in the regions where ResMed sells NightOwl today and will continually assess other opportunities. For millions of people, their best night’s sleep must start with a diagnosis.” “We believe Ectosense’s digital and easy-to-use solutions in the hands of both sleep lab technicians and consumers worldwide can help significantly increase diagnoses, as well as general awareness of this highly prevalent, 100% treatable disease. “Sleep labs and home tests each have critical roles to play in expanding our reach and identifying the 936 million people worldwide who have sleep apnea,” says Jim Hollingshead, ResMed president of Sleep & Respiratory Care, in a release. ResMed will continue to sell its ResMed ApneaLink Air home sleep test device “it’s enabled sleep labs, doctors, and other clinicians to process over 1.5 million diagnostic sleep tests in the cloud,” according to the ResMed spokesperson. A ResMed spokesperson notes in an email to Sleep Review that the NightOwl disposable HST is consumer-friendly because “it is digital and easy to use in lab or at home.” ResMed has distributed NightOwl in Australia and India since 2020 under the brand “ResMed onesleeptest,” and has been a minority investor in Ectosense since July 2020. ResMed today has completed the acquisition of Ectosense, makers of the NightOwl cloud-connected home sleep test (HST).Įctosense’s FDA-approved NightOwl is sold in the United States, Australia, New Zealand, India, and parts of Europe.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |